Patents by Inventor Daniel D. Long

Daniel D. Long has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Quinolinone-carboxamide compounds as 5-HT4 receptor agonists
    Patent number: 9353106
    Abstract: The invention provides novel quinolinone-carboxamide 5-HT4 receptor agonist compounds. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat diseases associated with 5-HT4 receptor activity, and processes and intermediates useful for preparing such compounds.
    Type: Grant
    Filed: January 13, 2015
    Date of Patent: May 31, 2016
    Assignee: Theravance Biopharma R&D IP, LLC
    Inventors: Daniel Marquess, Paul R. Fatheree, S. Derek Turner, Daniel D. Long, Seok-Ki Choi, Adam A. Goldblum
  • Inhibitors of hepatitic C virus
    Patent number: 9260414
    Abstract: The invention provides compounds of formula (I): wherein the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are inhibitors of replication of the hepatitis C virus. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat hepatitis C viral infections, and processes and intermediates useful for preparing such compounds.
    Type: Grant
    Filed: November 12, 2014
    Date of Patent: February 16, 2016
    Assignee: Theravance Biopharma R&D IP, LLC
    Inventors: Robert Murray McKinnell, Daniel D. Long, Lori Jean Van Orden, Lan Jiang, Mandy Loo, Daisuke Roland Saito, Sheila Zipfel, Eric L. Stangeland, Kassandra Lepack, Gavin Ogawa
  • HEPATITIS C VIRUS INHIBITORS
    Publication number: 20160038483
    Abstract: The invention provides compounds of formula (I): wherein the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are inhibitors of replication of the hepatitis C virus. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat hepatitis C viral infections, and processes and intermediates useful for preparing such compounds.
    Type: Application
    Filed: October 15, 2015
    Publication date: February 11, 2016
    Applicant: THERAVANCE BIOPHARMA R&D IP, LLC
    Inventors: Daniel D. Long, Robert Murray McKinnell, Lan Jiang, Mandy Loo, Kassandra Lepack, Lori Jean Van Orden, Gavin Ogawa
  • Hepatitis C virus inhibitors
    Patent number: 9212168
    Abstract: The invention provides compounds of formula (I): wherein the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are inhibitors of replication of the hepatitis C virus. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat hepatitis C viral infections, and processes and intermediates useful for preparing such compounds.
    Type: Grant
    Filed: November 2, 2012
    Date of Patent: December 15, 2015
    Assignee: Theravance Biopharma R&D IP, LLC
    Inventors: Daniel D. Long, Robert Murray McKinnell, Lan Jiang, Mandy Loo, Kassandra Lepack, Lori Jean Van Orden, Gavin Ogawa
  • 8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists
    Patent number: 9206172
    Abstract: The invention provides novel 8-azabicyclo[3.2.1]octane compounds of formula (I): wherein R1, R2, R3, A, and G are defined in the specification, or a pharmaceutically-acceptable salt or solvate thereof, that are antagonists at the mu opioid receptor. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat conditions associated with mu opioid receptor activity, and processes and intermediates useful for preparing such compounds.
    Type: Grant
    Filed: November 6, 2014
    Date of Patent: December 8, 2015
    Assignee: Theravance Biopharma R&D IP, LLC
    Inventors: Daniel D. Long, John R. Jacobsen, Lan Jiang, Daisuke Roland Saito, Ioanna Stergiades
  • Piperazine-piperidine compounds as hepatitis C virus inhibitors
    Patent number: 9206159
    Abstract: The invention provides compounds of formula (I): wherein the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are inhibitors of replication of the hepatitis C virus. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat hepatitis C viral infections, and processes and intermediates useful for preparing such compounds.
    Type: Grant
    Filed: April 24, 2013
    Date of Patent: December 8, 2015
    Assignee: Theravance Biopharma R&D IP, LLC
    Inventors: Daniel D. Long, Robert Murray McKinnell, Lori Jean Van Orden, Gavin Ogawa, Donna Wilton
  • 8-azabicyclo[3.2.1]octyl-2-hydroxybenzamide compounds as mu opioid receptor antagonists
    Patent number: 9199993
    Abstract: The invention provides 8-azabicyclo[3.2.1]octyl-2-hydroxybenzamide compounds of formula (I): wherein R2, R7, and m are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are antagonists at the mu opioid receptor. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat conditions associated with mu opioid receptor activity, and processes and intermediates useful for preparing such compounds.
    Type: Grant
    Filed: June 26, 2014
    Date of Patent: December 1, 2015
    Assignee: THERAVANCE BIOPHARMA R&D IP, LLC
    Inventors: Daisuke Roland Saito, Daniel D. Long, Lan Jiang, Bryan Frieman
  • 4-[2-(2-fluorophenoxy methyl)phenyl]piperidine compounds
    Patent number: 9162982
    Abstract: The invention relates to compounds of formula I: where a, R1, and R3-6 are as defined in the specification, or a pharmaceutically acceptable salt thereof. The compounds of formula I are serotonin and norepinephrine reuptake inhibitors. The invention also relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process and intermediates for preparing such compounds.
    Type: Grant
    Filed: November 4, 2013
    Date of Patent: October 20, 2015
    Assignee: Theravance Biopharma R&D IP, LLC
    Inventors: Lori Jean Patterson, Eric L. Stangeland, Sheila Zipfel, Daniel D. Long
  • 8-AZABICYCLO[3.2.1]OCTANE COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS
    Publication number: 20150291579
    Abstract: The invention provides novel 8-azabicyclo[3.2.1]octane compounds of formula (I): wherein R1, R2, R3, A, and G are defined in the specification, or a pharmaceutically-acceptable salt or solvate thereof, that are antagonists at the mu opioid receptor. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat conditions associated with mu opioid receptor activity, and processes and intermediates useful for preparing such compounds.
    Type: Application
    Filed: November 6, 2014
    Publication date: October 15, 2015
    Applicant: THERAVANCE BIOPHARMA R&D IP, LLC
    Inventors: Daniel D. Long, John R. Jacobsen, Lan Jiang, Daisuke Roland Saito, Ioanna Stergiades
  • QUINOLINONE-CARBOXAMIDE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS
    Publication number: 20150291580
    Abstract: The invention provides novel quinolinone-carboxamide 5-HT4 receptor agonist compounds. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat diseases associated with 5-HT4 receptor activity, and processes and intermediates useful for preparing such compounds.
    Type: Application
    Filed: January 13, 2015
    Publication date: October 15, 2015
    Applicant: THERAVANCE BIOPHARMA R&D IP, LLC
    Inventors: DANIEL MARQUESS, PAUL R. FATHEREE, S. DEREK TURNER, DANIEL D. LONG, SEOK-KI CHOI, ADAM A. GOLDBLUM
  • HEPATITIS C VIRUS INHIBITORS
    Publication number: 20150252023
    Abstract: The invention provides compounds of formulas (I) or (II): wherein the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are inhibitors of replication of the hepatitis C virus. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat hepatitis C viral infections, and processes and intermediates useful for preparing such compounds.
    Type: Application
    Filed: May 21, 2015
    Publication date: September 10, 2015
    Applicant: THERAVANCE BIOPHARMA R&D IP, LLC
    Inventors: Robert Murray McKinnell, Daniel D. Long
  • NEPRILYSIN INHIBITORS
    Publication number: 20150210690
    Abstract: In one aspect, the invention relates to compounds having the formula I: where R1-R6 are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising these compounds; methods of using these compounds; and processes and intermediates for preparing these compounds.
    Type: Application
    Filed: January 29, 2015
    Publication date: July 30, 2015
    Applicant: THERAVANCE BIOPHARMA R&D IP, LLC
    Inventors: Melissa Fleury, Anne-Marie Beausoliel, Adam D. Hughes, Daniel D. Long, Donna A.A. Wilton
  • NEPRILYSIN INHIBITORS
    Publication number: 20150209352
    Abstract: In one aspect, the invention relates to compounds having the formula I: where R1, R2a, R2b, and R3-R6 are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising these compounds; methods of using these compounds; and processes and intermediates for preparing these compounds.
    Type: Application
    Filed: January 29, 2015
    Publication date: July 30, 2015
    Applicant: THERAVANCE BIOPHARMA R&D IP, LLC
    Inventors: Melissa Fleury, Anne-Marie Beausoliel, Adam D. Hughes, Daniel D. Long, Donna A.A. Wilton
  • BENZIMIDAZOLE-CARBOXAMIDE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS
    Publication number: 20150183761
    Abstract: The invention relates to benzimidazole-carboxamide 5-HT4 receptor agonist compounds of formula (I) wherein R1 and X are as defined in the specification, or a pharmaceutically acceptable salt or solvate or stereoisomer thereof. The invention also relates to pharmaceutical compositions comprising such compounds, methods of using such compounds to treat diseases associated with 5-HT4 receptor activity, and processes and intermediates useful for preparing such compounds.
    Type: Application
    Filed: September 17, 2014
    Publication date: July 2, 2015
    Applicant: THERAVANCE BIOPHARMA R&D IP, LLC
    Inventors: Robert Murray McKinnell, Lan Jiang, Daniel D. Long
  • Hepatitis C virus inhibitors
    Patent number: 9066944
    Abstract: The invention provides compounds of formulas (I) or (II): wherein the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are inhibitors of replication of the hepatitis C virus. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat hepatitis C viral infections, and processes and intermediates useful for preparing such compounds.
    Type: Grant
    Filed: April 24, 2013
    Date of Patent: June 30, 2015
    Assignee: Theravance Biopharma R&D IP, LLC
    Inventors: Robert Murray McKinnell, Daniel D. Long
  • NOVEL INHIBITORS OF HEPATITIC C VIRUS
    Publication number: 20150071878
    Abstract: The invention provides compounds of formula (I): wherein the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are inhibitors of replication of the hepatitis C virus. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat hepatitis C viral infections, and processes and intermediates useful for preparing such compounds.
    Type: Application
    Filed: November 12, 2014
    Publication date: March 12, 2015
    Applicant: THERAVANCE BIOPHARMA R&D IP, LLC
    Inventors: Robert Murray McKinnell, Daniel D. Long, Lori Jean Van Orden, Lan Jiang, Mandy Loo, Daisuke Roland Saito, Sheila Zipfel, Eric L. Stangeland, Kassandra Lepack, Gavin Ogawa
  • 3-carboxypropyl-aminotetralin derivatives and related compounds as mu opioid receptor antagonists
    Patent number: 8969370
    Abstract: The invention provides 3-carboxypropyl-aminotetralin compounds of formula (I): wherein R1, R2, R3, R4, R5, and R6 are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are antagonists at the mu opioid receptor. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat conditions associated with mu opioid receptor activity, and processes and intermediates useful for preparing such compounds.
    Type: Grant
    Filed: March 4, 2014
    Date of Patent: March 3, 2015
    Assignee: Theravance Biopharma R&D IP, LLC
    Inventors: Sean G. Trapp, Michael R. Leadbetter, Daniel D. Long, Pierre-Jean Colson, Miroslav Rapta, Ying Yu
  • Quinolinone-carboxamide compounds as 5-HTreceptor agonists
    Patent number: 8962653
    Abstract: The invention provides novel quinolinone-carboxamide 5-HT4 receptor agonist compounds. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat diseases associated with 5-HT4 receptor activity, and processes and intermediates useful for preparing such compounds.
    Type: Grant
    Filed: October 1, 2013
    Date of Patent: February 24, 2015
    Assignee: Theravance Biopharma R&D IP, LLC
    Inventors: Daniel Marquess, Paul R. Fatheree, S. Derek Turner, Daniel D. Long, Seok-Ki Choi, Adam A. Goldblum, Daniel Genov
  • 8-AZABICYCLO[3.2.1]OCTYL-2-HYDROXYBENZAMIDE COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS
    Publication number: 20150051243
    Abstract: The invention provides 8-azabicyclo[3.2.1]octyl-2-hydroxybenzamide compounds of formula (I): wherein R2, R7, and m are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are antagonists at the mu opioid receptor. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat conditions associated with mu opioid receptor activity, and processes and intermediates useful for preparing such compounds.
    Type: Application
    Filed: June 26, 2014
    Publication date: February 19, 2015
    Applicant: THERAVANCE BIOPHARMA R&D IP, LLC
    Inventors: Daisuke Roland Saito, Daniel D. Long, Lan Jiang, Bryan Frieman
  • Amino- and amido-aminotetralin derivatives and related compounds as mu opioid receptor antagonists
    Patent number: 8952031
    Abstract: The invention provides amino- and amido-aminotetralin compounds of formula (I): wherein R1, R2, R3, R4, R5, R6, R7, and n are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are antagonists at the mu opioid receptor. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat conditions associated with mu opioid receptor activity, and processes and intermediates useful for preparing such compounds.
    Type: Grant
    Filed: March 5, 2012
    Date of Patent: February 10, 2015
    Assignee: Theravance Biopharma R&D IP, LLC
    Inventors: Sean G. Trapp, Michael R. Leadbetter, Daniel D. Long, Lan Jiang, Sabine Axt